A Phase 2, Randomized Dose-Finding Study of Tapinarof (GSK2894512 Cream) for the Treatment of Plaque Psoriasis

Novel topical treatments for psoriasis have not been developed for many years. Tapinarof, a therapeutic AhR modulating agent, is a potential new treatment option for psoriasis patients. Tapinarof, delivered in a 1% cream, achieved ≥75% improvement in Psoriasis Area and Severity Index in 60% of patients treated once daily.

https://ift.tt/2O6XpRT